Patents by Inventor Fortuna Haviv

Fortuna Haviv has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030050246
    Abstract: Compounds having the formula
    Type: Application
    Filed: July 26, 2001
    Publication date: March 13, 2003
    Inventors: Fortuna Haviv, Michael F. Bradley, Douglas M. Kalvin, Jack Henkin
  • Publication number: 20030045477
    Abstract: Compounds having the formula
    Type: Application
    Filed: July 26, 2002
    Publication date: March 6, 2003
    Inventors: Fortuna Haviv, Michael F. Bradley, Douglas M. Kalvin, Jack Henkin
  • Publication number: 20020183242
    Abstract: The present invention discloses peptides which are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
    Type: Application
    Filed: April 11, 2001
    Publication date: December 5, 2002
    Inventors: Jack Henkin, Fortuna Haviv, Michael F. Bradley, Douglas M. Kalvin, Andrew J. Schneider
  • Patent number: 6387885
    Abstract: Disclosed are 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: May 14, 2002
    Assignee: Abbott Laboratories
    Inventors: Christopher R. Dalton, Milan Bruncko, Michele A. Kaminski, Lisa M. Frey, Daryl R. Sauer, Fortuna Haviv
  • Patent number: 6297354
    Abstract: The present invention relates to a class of pentapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: October 2, 2001
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Wesley Dwight, Jonathan Greer
  • Patent number: 6191115
    Abstract: The present invention relates to a class of heptapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: February 20, 2001
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Wesley J. Dwight, Charles J. Nichols, Jonathan Greer
  • Patent number: 6020521
    Abstract: Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: February 1, 2000
    Assignee: Abbott Laboratories
    Inventors: John T. Randolph, Fortuna Haviv, Daryl Sauer, Philip Waid, Charles J. Nichols, Nicholas A. Mort, Christopher R. Dalton, Jonathan Greer
  • Patent number: 5981521
    Abstract: Tetrahydroisoquinoline derivatives of the formula: ##STR1## or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: November 9, 1999
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Wesley J. Dwight, Bradley W. Crawford, Rolf E. Swenson, Milan Bruncko, Michele A. Kaminski, Lisa M. Frey, John DeMattei, Jonathan Greer
  • Patent number: 5972898
    Abstract: Disclosed are 3',3'-N-bisdesmethyl-3',3'-N-bis-substituted-6-O-methyl-11-deoxy-11,12-cyc lic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: October 26, 1999
    Assignee: Abbott Laboratories
    Inventors: Daryl R. Sauer, Fortuna Haviv, John Randolph, Nicholas A. Mort, Christopher R. Dalton, Milan Bruncko, Michele A. Kaminski, Bradley W. Crawford, Lisa Marie Frey, Jonathan Greer
  • Patent number: 5955440
    Abstract: Disclosed are 3'-N-desmethyl-3'-N-substituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: September 21, 1999
    Assignee: Abbott Laboratories
    Inventors: Daryl R. Sauer, Fortuna Haviv, John Randolph, Nicholas A. Mort, Christopher R. Dalton, Milan Bruncko, Michele A. Kaminski, Bradley W. Crawford, Lisa Marie Frey, Jonathan Greer
  • Patent number: 5698522
    Abstract: The present invention provides a class of decapeptide compounds which are potent antagonists of LHRH activity and which have the structure A.sup.1 -D.sup.2 -E.sup.3 -G.sup.4 -J.sup.5 -L.sup.6 -M.sup.7 -Q.sup.8 -R.sup.9 -T.sup.10. The compounds of the percent invention are characterized by having an .OMEGA.-amino-functionalized side chain on the D-aminoacyl residue at position 6. The .OMEGA.-amino group of this side chain is further derivatized by the attachment of an extending group which likewise has a terminal amino group which is capped by an acyl group.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 16, 1997
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort, Jonathan Greer
  • Patent number: 5516647
    Abstract: The present invention discloses novel compounds useful as alkaline phosphatase inhibitors and therapeutic agents. Preferably, the novel compounds are useful as selective inhibitors of human alkaline phosphatases as opposed to Escherichia coli alkaline phosphatases. The novel compounds can also be used as cancer therapeutic agents, anti-depressive agents, anti-anergic agents, and antihelminthic agents. The novel compounds have the following general formula: ##STR1## wherein R' is an aryl, aryl ether, aryl thioether, aromatic heterocyclic, aromatic heterocyclic thioether, or aromatic heterocyclic ether group. More preferably, R' is a phenyl or a pyridine. Most preferably, R' is of the following formula: ##STR2## 2-thiopyridine, or ##STR3## 2-oxypyridine. R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.1 ', R.sub.2 ', R.sub.3 ', R.sub.4 ', and R.sub.5 ' can be the same or different, and at least one of which is selected from the group consisting of: H, C.sub.1 -C.sub.6 alkyl, halo C.sub.1 -C.sub.6 alkyl, phenyl, C.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: May 14, 1996
    Assignee: Abbott Laboratories
    Inventors: Mazhar Husain, Dominique Bridon, Mark Bures, James D. Ratajczyk, Fortuna Haviv, Christopher Bieniarz
  • Patent number: 5516759
    Abstract: Peptides possessing LHRH antagonistic activity, and useful for the controlling the release of LHRH in mammals are decapeptide analogues of LHRH having a lactam group at the N-terminus of the formula ##STR1## where n is 1, 2, or 3 and R.sup.1 is selected from the group consisting of hydrogen, benzyl, 4-chlorobenzyl, 2-methylnaphth-1-yl, 1-methylnaphth-2-yl, and quinolin-3-ylmethyl.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: May 14, 1996
    Assignee: TAP Holdings Inc.
    Inventors: Rolf E. Swenson, Fortuna Haviv, Nicholas A. Mort
  • Patent number: 5508383
    Abstract: A class of cyclic peptides are effective inhibitors of LHRH and are useful in the treatment of disease conditions which are mediated by sex hormones including prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
    Type: Grant
    Filed: March 9, 1994
    Date of Patent: April 16, 1996
    Assignee: Tap Holdings Inc.
    Inventors: Daryl R. Sauer, Fortuna Haviv
  • Patent number: 5502035
    Abstract: Decapaptide and undecapaptides substituted on the N-terminal nitrogen atom by acyl groups which include furo-2-yl, isonicotinyl, nicotinyl, 2-, 3-, and 4-quinolinecarbonyl, shikimyl, dihydroshikimyl, and tetrahydrofur-2-oyl are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: March 26, 1996
    Assignee: Tap Holdings Inc.
    Inventors: Fortuna Haviv, Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort
  • Patent number: 5491217
    Abstract: A class of potent LHRH decapeptide antagonists possess N-alkylated aminoacyl residues where the side-chain portion of the residue is a 4-(substimtedamino)phenylalanyl, 4-(substituted-amino)cyclohexylalanyl, or .OMEGA.-(substitutedamino)alkyl group, and additionally the aminoacyl residues at position 5 are N-alkylated on the nitrogen atom of the peptide backbone.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: February 13, 1996
    Assignee: TAP Holding Inc.
    Inventors: Fortuna Haviv, Jonathan Greer, Rolf E. Swenson, Daryl R. Sauer
  • Patent number: 5432263
    Abstract: The present invention provides a process for the preparation of peptides which have or side-chains containing an alkyl- or dialkyl-substituted guanidinyl group or a imidazinylamino or tetrahydropyrimidinylamino group. The process provides higher overall yields of peptide product by permitting the synthesis of the entire peptide chain prior to modification of the side-chain to introduce the groups.
    Type: Grant
    Filed: January 28, 1994
    Date of Patent: July 11, 1995
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Rolf E. Swenson, Timothy D. Fitzpatrick
  • Patent number: 5413990
    Abstract: Decapaptides substituted on the N-terminal nitrogen atom by acyl groups are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: May 9, 1995
    Assignee: Tap Pharmaceuticals Inc.
    Inventors: Fortuna Haviv, Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort
  • Patent number: 5300492
    Abstract: The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.
    Type: Grant
    Filed: October 28, 1991
    Date of Patent: April 5, 1994
    Assignee: Tap Pharmaceuticals
    Inventors: Fortuna Haviv, Jonathan Greer
  • Patent number: 5140009
    Abstract: The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids, 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.
    Type: Grant
    Filed: July 10, 1990
    Date of Patent: August 18, 1992
    Assignee: Tap Pharmaceuticals, Inc.
    Inventors: Fortuna Haviv, Jonathan Greer, Christopher A. Palabrica, Timothy D. Fitzpatrick